Mice treated solely with anti-VEGF therapies confirmed the team's findings in human patients: although VEGF levels dropped, ANGPTL4 levels increased, which inhibited the anti-VEGF therapies' effectiveness in reducing blood vessel growth and vision loss. Additional study authors include Deepti Sharma, Evan Lau, Yu Qin, Murilo Rodrigues, Chuanyu Guo, Emma McIntyre, Shaima Salman, Yousang Hwang, and Gregg L. Semenza of Johns Hopkins University School of Medicine; Aumreetam Dinabandhu and Silvia Montaner of the University of Maryland; and Ala Moshiri of the University of California, Davis. AdobeStock/spainter_vfx) A new study from researchers at the Wilmer Eye Institute, Johns Hopkins Medicine, reveals why some patients with wet age-related macular degeneration (wet AMD) fail to experience vision improvement with current treatments and how an experimental drug could enhance existing wet AMD therapies to preserve vision. https://www.modernretina.com/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fmodernretina%2F131de946654562d9ea2b8ebbf64c7ebba09dd808-1200x634.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 https://cdn.sanity.io/images/0vv8moc6/modernretina/131de946654562d9ea2b8ebbf64c7ebba09dd808-1200x634.jpg?fit=crop&auto=format...

Researchers offer insights into wet AMD: Study reveals potential to enhance anti-VEGF therapy with experimental drug to preserve vision